Rhea-AI Summary
Frequency Therapeutics (Nasdaq: FREQ) has announced a strategic update on FX-322, its lead candidate for treating acquired sensorineural hearing loss (SNHL). The company will share analysis of day-90 data from its Phase 2a study in late Q1 2021, following improvements seen in a previous Phase 1/2 study. The Phase 2a study aims to confirm hearing signal and assess multiple doses while expanding the program to include age-related and severe SNHL patients. Key milestones include data readouts for Phase 2a by late Q2 2021 and ongoing Phase 1b studies. Management projects significant clinical insights in early 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags